Amylin: indexed trial records

This page carries 12 of the 3,167 records the literature query returned for Amylin, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index.

Every row below resolves to a real identifier and names the study model the indexer assigned. The record class is read from the publication type on the record itself. Nothing here states what a record found.

At a glance

Class

Amylin and amylin receptor agonists

Receptor targets as recorded

Amylin receptor, Calcitonin receptor

Records indexed here

12

Records returned by the query

3,167

Publication years covered

2006–2017

Query retrieved

2026-10-12

Shape of the indexed record set

Study model is the indexer’s own assignment, taken from the MeSH population headings and the publication type. It is not a judgement about how well a record was conducted.

Endpoint coverage

1 of the 12 records here carry no subject heading from any endpoint set used on this site, so they appear under no endpoint.

Derived record-set tier

Animal and in vitro only (INFERRED, derived from record counts)
Basis: no interventional human trial record; 2 rodent and 0 in vitro records among 12.
This label counts record types. It is not an assessment of clinical efficacy, of safety, of study quality or of consensus, and it does not rank one compound above another.

What the corpus does not carry for this compound

• Identity fields with no source retrieved: uniprot_id, sequence.
• Reported half-life: no source retrieved, so the value reads Unknown.
• Amounts reported in the cited literature: no row recorded.
• Adverse effects reported in the cited literature: no row recorded.
• Long-form mechanism: not written, because no source was read in full.
• Records the query returned that this corpus does not carry: 3,155.

An absent row records the absence of a retrieved report, never the absence of the thing itself.

Application register

A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.^[2]

Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.

The records

Where this page sits

Receptor targets

• Amylin receptor: every compound in scope acting at it
• Calcitonin receptor: every compound in scope acting at it

All compounds in scope: the trial index. Coverage by endpoint: the endpoint index.

Review status

Review tier

High impact

State

Pending qualified review

Compiled by

automated pipeline

Qualified clinical review

None on record

Why this tier was assigned

• the class covers weight-management and metabolic prescribing, the highest-risk consumer subject in this corpus

Checks the pipeline performed

• every cited source id resolves to a sources[] row on the entity
• every identifier is a well-formed PMID or DOI
• study model derived only from assigned MeSH headings and publication types
• banned-phrase lint over rendered HTML including title, meta, alt and JSON-LD
• unknown values render as the literal word Unknown

Checks the pipeline did not perform

• no full text was read
• no clinical appraisal of any study
• no assessment of whether the indexed set is representative of the literature

A high_impact profile with qualified_review null must not be published as indexable. Compilation and linting are not clinical validation.

Sources

1. PubChem Compound Summary for CID 16132430, Islet Amyloid Polypeptide. PubChem, National Library of Medicine (2026). pubchem:16132430
2. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:amylin
3. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological reviews (2011). pmid:21742788
4. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacological reviews (2002). pmid:12037140
5. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Molecular pharmacology (1999). pmid:10385705
6. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature (1988). pmid:3050530
7. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proceedings of the National Academy of Sciences of the United States of America (1990). pmid:2195544
8. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature (1994). pmid:8152488
9. Pore formation by the cytotoxic islet amyloid peptide amylin. The Journal of biological chemistry (1996). pmid:8567648
10. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes (1999). pmid:10078548
11. Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry (2007). pmid:17979302
12. Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. Proceedings of the National Academy of Sciences of the United States of America (2008). pmid:18408164
13. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nature immunology (2010). pmid:20835230